Second-Generation Antimitotics in Cancer Clinical Trials
Mitosis represents a promising target to block cancer cell proliferation. Classical antimitotics, mainly microtubule-targeting agents (MTAs), such as taxanes and vinca alkaloids, are amongst the most successful anticancer drugs. By disrupting microtubules, they activate the spindle assembly checkpoi...
Main Authors: | Pedro Novais, Patrícia M. A. Silva, Isabel Amorim, Hassan Bousbaa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/7/1011 |
Similar Items
-
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents
by: Oakley C. Olson, et al.
Published: (2017-04-01) -
Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel
by: Joana Fonseca, et al.
Published: (2016-07-01) -
Natural products as new antimitotic compounds for anticancer drug development
by: Carlos Roberto Koscky Paier, et al.
Published: (2018-12-01) -
Antiproliferative Fate of the Tetraploid Formed after Mitotic Slippage and Its Promotion; A Novel Target for Cancer Therapy Based on Microtubule Poisons
by: Yuji Nakayama, et al.
Published: (2016-05-01) -
Effectors of the spindle assembly checkpoint are confined within the nucleus of Saccharomyces cerevisiae
by: Lydia R. Heasley, et al.
Published: (2019-06-01)